Statins are among the most prescribed drugs in the world and are first-line therapy in the management of hyperlipidemia. Their beneficial effects on cardiovascular morbidity and mortality have been demonstrated both in primary and in secondary prevention. 1, 2 They are generally safe, but in some patients, statin therapy is stopped because of intolerance to the drug that may result in muscle aches and weakness, gastrointestinal symptoms, liver enzyme abnormalities, or other nonspecific discomforts. The rate of reported statin-related events is about 5% to 10% in randomized, placebocontrolled clinical trials. 3, 4 This rate has been reported as high as 20% in observational studies. [5] [6] [7] [8] [9] [10] The discrepancy between clinical trials and observational studies can be explained by patient selection in randomized trials, which often exclude old patients and those with many comorbidities and enroll few women.
Some adverse effects of statin therapy such as muscle pain and liver enzymes abnormalities are thought to be dose related. 11 It is recognized that 20% to 40% low-density lipoprotein cholesterol (LDL-C) reduction can be achieved with the lowest daily dose of statins approved. Furthermore, an additional 6% to 7% can be achieved with each doubling of the dose. 12 Nevertheless, in some patients, daily dosing of statin or the lowest approved doses are not tolerated.
The intermittent dosing strategy has been suggested recently and mostly with rosuvastatin because of its long half-life, high potency, and favorable metabolic characteristics. [13] [14] [15] [16] However, previous studies are small. The aim of this study is to review the different treatment strategies used to improve lipid profiles in patients with prior statin intolerance treated at a large tertiary prevention clinic, with a focus on intermittent statin dosing.
Methods
We reviewed the electronic records of patients referred to the Cleveland Clinic Preventive Cardiology Section for statin intolerance between January 1995 and March 2010. We used the Preventive Cardiology Information System database, which contains information from patients referred to this clinic. At the time of baseline visit, demographic information, medical history, physical examination, and laboratory data are obtained and entered into an electronic medical record. Patients are classified as statin intolerant based on their medical history and information provided by themselves or the referring physician. A comprehensive history of statin intolerance including drugs involved, doses, and symptoms was taken. We used American College of Cardiology/American Heart Association definitions for myalgia (muscle ache or weakness without creatinine kinase [CK] elevation), myositis (muscle symptoms with CK elevation), and rhabdomyolysis (muscle symptoms with CK N10× upper limit of normal and elevation of creatinine). 17 Preventive Cardiology Information System database analyses are approved by the Cleveland Clinic institutional review board. We identified 1,605 consecutive patients with documented intolerance to at least 2 statin medications and at least a 6-month follow-up with a stable form of lipid-lowering therapy. Patients were divided into 3 groups based on their statin regimen at the time of their last follow-up visit: no statin, intermittent statin dosing, or daily statin dosing.
Intermittent statin dosing is defined as any statin prescription that is not taken on a daily basis notwithstanding the dose. All subjects received nutritional recommendations and education as a routine part of each patient visit.
We evaluated different prescriptive strategies used in those patients to improve their lipid profiles and analyzed the changes in their lipid profile. The primary outcomes of the study were the percent change in fasting lipid profiles from baseline to the last follow-up visit and the percentage of patients achieving the specified National Cholesterol Education Program Adult Treatment Panel III (ATP-III) LDL-C goals. The secondary outcome was all-cause mortality difference between the different treatment strategies. A direct LDL-C was automatically obtained as a standard practice if triglyceride (TG) level was N250 mg/dL. Otherwise, LDL-C was calculated using the Friedewald equation. 18 No extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
Statistical analysis
Patient characteristics of the 3 groups of statinintolerant patients are presented as mean ± SD for continuous variables with normal distribution (median and 25th and 75th percentiles for nonnormally distributed data) and percents for categorical variables. Comparisons of continuous data were made using analysis of variance for normally distributed data and Kruskal-Wallis for nonnormally distributed data. Categorical data were compared using χ 2 or exact tests. Percent changes in total cholesterol (TC), LDL-C, highdensity lipoprotein cholesterol (HDL-C), and TG from baseline to the last follow-up visit were calculated and were natural logarithmically transformed, if necessary.
Linear regression models were used to calculate least square means, and comparisons of the percent changes in the lipid parameters across statin dosing strategies were performed with adjustment variables including the baseline lipid parameter and other lipid-lowering agents (fibrates, ezetimide, niacin, red yeast rice, Metamucil, (Protor & Gamble, Cincinnati, OH) phytosterols, bile acid resins, flaxseed).
All-cause mortality was assessed, as determined by the Social Security Death Index (SSDI). Kaplan-Meier methods were used to estimate 8-year survival. Time to event for patients who did not have follow-up beyond 8 years or died was censored. To the date, the SSDI was accessed for this study. Log-rank P values were computed to compare survival rates across statin dosing strategies.
A P value less than .05 was considered statistically significant. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
Results
During the median follow-up time of 31 months, 72.5% (n = 1,163) of the subjects remained on a regular regimen of statin therapy, with 63.2% (n = 1,014) on a daily regimen and 9.3% (n = 149) on an intermittent statin regimen. Statins were completely discontinued for 27.5% (n = 442) of patients. The patients' demographics are presented in Table I . Most patients were female (n = 919; 57%) and whites (n = 1,347; 84%). There were a higher proportion of men in the daily statin dosing group. Patients in the daily statin group were relatively younger. The study population was relatively obese, with a mean body mass index of 30 kg/m 2 . Based on the Framingham risk score assessment for the determination of the LDL-C goal, 65% of the patients were classified as moderate or high risk for CHD, which corresponds with an LDL goal of less than 130 or 100 mg/dL, respectively. Although the proportion of patients with CHD was higher in the daily statin and intermittent groups compared with the statin discontinued group, there was no significant difference in the overall Framingham risk score categories. There were a higher proportion of patients with kidney disease (glomerulonephritis, chronic kidney disease, or polycystic kidney disease) and liver disease (cirrhosis, hepatitis B or C, fatty liver disease) in the statin discontinued group. Overall, 42% of the patients were treated for secondary prevention, with a higher proportion in the daily statin dosing group. Patients were not at their LDL goal at their first visit to the clinic. The mean LDL was 144 ± 58 mg/ dL. Patients in the intermittent statin dosing group had a higher baseline mean LDL-C compared with the other 2 groups.
The profile of statin intolerance is described in Table I . The most common complaint of statin intolerance was myalgia, with a higher proportion in the statin intermittent group. There were a higher proportion of patients with pancreatitis (significant elevation of serum amylase or lipase) in the statin discontinued group. The intermittent statin group had more complaints of neurologic symptoms. There was no significant difference for all the other symptoms.
Seventy-two percent of patients reported prior intolerance to atorvastatin, 44% to simvastatin, 26% to rosuvastatin, and 20% to pravastatin, reflecting the fact that these ALT, Alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; CHD, coronary heart disease; CHF, congestive heart failure; CVD, cerebral vascular disease; TSH, thyroid-stimulating hormone.
statins were the most used statins. As would be expected, the proportions of patients intolerant to different statins were higher in the intermittent dosing and the discontinued groups compared with the daily statin dosing group. The intermittent dosing group had higher proportions of patients intolerant to other lipid-lowering drugs including fibrates, niacin, ezetimide, and bile acid sequestrants. Of the 1,605 patients referred to our clinic for statin intolerance, 72.5% were ultimately able to tolerate some form of long-term statin therapy regimen. Most patients who tolerated long-term statin were on rosuvastatin (43%). Rosuvastatin was the single most used statin in the intermittent dosing group (75.2%). In the daily dosing group, other statins such as atorvastatin (21.5%), pravastatin (18.0%), and simvastatin (20.1%) were also used beside rosuvastsatin (38.3%). Concomitant lipid-lowering drugs were also heavily used in this population, including ezetimide (34%), niacin (21%), and nonprescription drugs such as omega-3 fatty acid (44%) and plant sterols (8%) ( Table II) . Although there was a heavier use of niacin, bile acid sequestrants, Metamucil, red yeast rice extract, and plant sterols in the intermittent dosing and the statin discontinued groups, there was no difference in the use of ezetimide and fibrates between the 3 groups. Coenzyme Q10 was used more often in the statin intermittent group. Other medications such angiotensinconverting enzyme inhibitor, aspirin, and β-blockers were used more often in the statin groups.
Patients who remained on daily or intermittently statin achieved a higher LDL-C reduction compared with those who discontinued statin (27.7% ± 1.4% vs 21.3% ± 4.0% vs 8.3% ± 2.2%, P b .001) (Table III, Figure 1 ). Patients on intermittent statin dosing achieved a lower LDL-C reduction compared with patients on daily statin dosing (21.3% ± 4.0% vs 27.7% ± 1.4%, P = .04). Although the statin discontinued group had a lower reduction in LDL-C than did those who stayed on statin, they still achieved significant LDL-C reductions from baseline (8.3% ± 2.2%, P b .001). Changes in TC paralleled changes in LDL-C, whereas changes in HDL-C and TGs were not statistically significant (Table III) . A greater proportion of patients achieved their ATP-III goals in the daily dosing group compared with the intermittent statin and the statin discontinued groups (79% vs 61% vs 44%, respectively; P b .001) (Table IV) . More patients achieved their ATP-III goals in the intermittent statin dosing group compared with the statin-discontinued group (P = .002).
A multivariate analysis was done to determine the factors affecting LDL-C changes. This analysis was adjusted for baseline LDL-C, statin use, and other lipidlowering therapies. The analysis shows that the LDL-C change was affected by the patient's gender (P = .002), history of cerebral vascular disease (P = .03), and peripheral vascular disease (PVD; P = .009), use of statin (P = .004), and niacin (P = .003) or welchol (P = .01). All the other parameters were nonsignificant for the model.
Using all-cause mortality as a dependent variable, Cox proportional hazard regression analysis was performed to determine whether statin use (both daily and intermittent) was significantly and independently associated with mortality. Significant variables in the final survival model of the multivariable analysis included patient's age (P b .001), history of heart failure (P b .004), and PVD (P b .04).
As shown by the Kaplan-Meier survival curves, there was a trend toward a decrease in 8-year all-cause mortality in patients on statins compared with those who discontinued statin, which did not attain statistical significance (P = .08) (Figure 2) .
Discussion
In the present study, we reviewed treatment strategies used in 1,605 patients with statin intolerance referred to a single institution and assessed serum lipid levels, tolerance of therapies, and all-cause mortality. In particular, we analyzed the tolerance and the efficacy of intermittent statin therapy. The most important finding of this study is that most statinintolerant patients can tolerate some form of statin therapy and that intermittent statin use can be an option for some patients to achieve improvement in serum lipid levels. The other interesting finding was the trend toward a survival benefit in patients who were able to tolerate some form of statin therapy compared with those who discontinued statin.
This study is the largest to date to review different treatment regimens for patients with documented statin intolerance and their impact on LDL-C.
It confirms previous reports that most patients with a history of statin intolerance can tolerate subsequent statin trials, achieve significant LDL-C reductions, and attain LDL-C goals.
In a recent study, Zhang et al 10 explored the frequency of statin discontinuation in 1 hospital system and analyzed data from 107,835 patients' medical records between January 1, 2000, and December 31, 2008. They found that most statin-intolerant patients (N90%) could ultimately tolerate a statin.
Our study shows that most patients (72.5%) who are "statin intolerant" can tolerate some form of statin therapy with a significant proportion (63.2%) on a daily statin regimen.
Statins have well-documented benefits, and their discontinuation has been associated with increased risk for cardiovascular events. 5, 19 The result of this and other studies suggests that for most patients who report statin-related events, especially high-risk patients, statin can safely be represcribed with a high probability of long-term tolerance.
Intermittent statin dosing is regarded as an interesting strategy in patients with statin-related symptoms. Nevertheless, most studies on the efficacy of this strategy are small. [13] [14] [15] [16] 20, 21 A recent review of several small studies by Marcus et al 22 suggests that alternate-day dosing of statin may achieve similar levels of LDL-C reduction compared with daily dosing and may improve tolerance. Backes et al 14 showed a mean LDL-C decrease of 34.5% in 51 patients on everyother-day rosuvastatin dosing. Gadarla et al 15 also showed a 26% LDL-C reduction with rosuvastatin 5 to 10 mg twice a week in 40 statin-intolerant patients. Ruisinger et al 21 achieved a 23% LDL-C reduction using rosuvastatin 5 to 20 mg once a week for 4 months in a group of 50 statinintolerant patients. A randomized, controlled trial of once-weekly rosuvastatin in statin-intolerant patients was published during the writing of this article. It included 17 patients and showed a 12% LDL reduction and 20% LDL goal achievement for 8 weeks. 23 Other statins including atorvastatin and simvastatin have also demonstrated effectiveness with intermittent dosing in small studies of limited duration. [24] [25] [26] An important conclusion of this analysis is that patients who could only tolerate intermittent statin regimens (9.3%) could still achieve acceptable LDL-C reduction (21.3% ± 4.0%) and ATP-III LDL-C goals (61%).
Intermittent dosing regimens in this study included different statins with various infrequent dosing strategies (from once weekly to 6 days a week). The average LDL-C reduction observed in this study (21.3% ± 4.0%) is consistent with the reductions shown in previous trials. Although some studies with atorvastatin, fluvastatin, and rosuvastatin have suggested that every-other-day dosing needs to be nearly twice the daily dose to yield similar LDL-C lowering, 21,27-29 our study shows that similar reductions can be achieved with the same and even low doses, in both daily and intermittent dosing strategies. Intermittent statin dosing can therefore be a useful strategy to improve statin use and tolerability. There are presently no data on a large randomized trial that demonstrates equivalent effects on clinical outcomes with intermittent dosing regimens as for the daily dosing. This study does, however, show a trend toward improved survival with any use of statin, either intermittent or daily. We believe that the observed trend, although not statistically significant, reinforces the belief that for patients who need statin therapy, we should strive to find some regimen that can be tolerated even if the dosage is as infrequent as once per week.
Finally, this study also shows that some patients who discontinued statin can still achieve significant LDL-C reduction and reach ATP-III goals with comprehensive lifestyle therapy and non-statin lipid-lowering drugs.
Limitations
There are several limitations to our study. First, this is an observational study reviewing historical data with no placebo controls in a single center. Second, statin intolerance symptoms were self-reported and not objectively assessed. Third, although a comprehensive medical and lifestyle therapy was provided to this population, nonprescriptive pharmacologic interventions such as exercise and diet were not systematically quantified or documented. It is therefore difficult to determine the contribution of statin alone to the overall LDL-C reduction compared with the cumulative alternative lipid-lowering efforts recommended to the patients. Fourth, compliance was not objectively assessed because of lack of data. Compliance is an important consideration in assessing the effectiveness of an intervention. Patients who are noncompliant on a daily statin regimen would actually fall into the intermittent dosing group. Fifth, the number of patients in the 3 different arms of the study is not balanced, and the number of patients with intermittent therapy is particularly small. This makes the comparison among the 3 groups somewhat difficult. Last, the exact Kaplan-Meier estimates of overall 8-year survival according to longterm statin use status. The log-rank P value comparing the statin group (daily and intermittent dosing strategies) versus the statin discontinued group is .08.
cause of death is not documented because the mortality data were obtained through the SSDI. This would have been interesting to know given the differences in liver disease, kidney disease, and pancreatitis. Despite the above-mentioned limitations, this study provides interesting data on the management of this very challenging group of patients. More studies are needed to verify whether intermittent statin regimens reduce cardiac events and prolong survival.
Conclusions
This study shows that prior statin intolerance does not preclude long-term statin therapy and achievement of ATP-III goals. Most patients with statin intolerance are able to maintain a stable long-term statin treatment regimen. A strategy of intermittent statin dosing can be an effective therapeutic option in some statin-intolerant patients and may result in reduction in LDL-C and achievement of LDL-C goals.
